SEC Form 4 · accession 0001203311-17-000038
SEATTLE GENETICS INC /WA · SGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Darren S Cline
Officer — EVP, Commercial
Period of report
Aug 7, 2017
Accepted (ET)
Aug 9, 2017 · 6:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001060736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 7, 2017 | M | 6,000 | $18.46 | A | 67,656 | D | |
| Common StockF1 | Aug 7, 2017 | S | 6,000 | $49.185 | D | 61,656 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $18.46 | Aug 7, 2017 | M | 6,000 | D | — | Feb 28, 2022 | Common Stock | 6,000 | 2,907 | D |
Explanation of responses
- F1Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting and 105 shares acquired under the Amended and Restated 2000 Employee Stock Purchase Plan on July 31, 2017.
- F2Shares vested at a rate of 25% on 2/28/2013 and monthly thereafter until all the shares were fully vested on 2/28/2016.